Back to search

Article

A Phase II Trial of the JAK-Inhibitor Ruxolitinib with Exemestane for Estrogen Receptor Positive, Aromatase Inhibitor Resistant, Advanced Breast Cancer

2022-06-01

Abstract excerpt

<title>Abstract</title> <p>PURPOSE Circulating IL-6, an activator of JAK/STAT signaling, is associated with poor outcomes and aromatase inhibitor (AI) resistance in hormone-receptor positive (HR+) breast cancer. We investigated the safety and efficacy of ruxolitinib, an oral selective inhibitor of JAK1/2, given with exemestane in patients with HR + metastatic breast cancer (MBC) after progression on a non-steroi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4070d4ce-8d2d-5aa9-a1df-069afdeef9f0
DOI
10.21203/rs.3.rs-1623128/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Phase II Trial of the JAK-Inhibitor Ruxolitinib with Exemestane for Estrogen Receptor Positive, Aromatase Inhibitor Resistant, Advanced Breast CancerDOI 10.21203/rs.3.rs-1623128/v1
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.Semantic proximity
Exemestane for primary prevention of breast cancer in postmenopausal women.Semantic proximity
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibitionSemantic proximity
Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.Semantic proximity
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.Semantic proximity
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?Semantic proximity
Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.Semantic proximity
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.Semantic proximity
Select a neighboring publication to make it the new centre.